Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia-Reference-Cited by-同舟云学术

Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia

Published:2021-01-22 Issue:3 Volume:100 Page:e24273
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Ye Li,Gao Lingsu,Cheng Qiansong,Guo Feng,He Liang,Yuan Tingting,Zhu Ming,Ma Yuanfang,Pan Min,Chu Xiandeng,Ding Meiqi,Yu Guohui

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference26 articles.

1. Acute myeloid leukaemia in adults;Ferrara;Lancet,2013

2. Cancer statistics, 2020;Siegel;CA Cancer J Clin,2020

3. An epidemiological investigation of leukemia incidence between 2003 and 2007 in Nanjing, China;Chen;J Hematol Oncol,2010

4. Adult acute myeloid leukemia;Jabbour;Mayo Clin Proc,2006

5. Acute myeloid leukemia--major progress over four decades and glimpses into the future;Kantarjian;Am J Hematol,2016

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medium-cumulative dose of cytarabine in consolidation therapy shows the greatest benefit in AML patients;Holistic Integrative Oncology;2024-05-21

2. Microcosting analysis of haematopoietic stem cell transplantation and chemotherapy with intermediate doses of cytarabine in the treatment of acute myeloid leukaemia;Hematology, Transfusion and Cell Therapy;2024-04

3. Single dose of peg GCSF compared with daily GCSF in de novo acute myeloid leukemia patients on high dose cytarabine consolidation chemotherapy (HIDAC);2024-01-05

4. Microcosting Analysis of Hematopoietic Stem Cell Transplantation and Chemotherapy with Intermediate Doses of Cytarabine in the Treatment of Acute Myeloid Leukemia;2023-02-16

5. Olive leaves extract alleviates inflammation and modifies the intrinsic apoptotic signal in the leukemic bone marrow;Frontiers in Immunology;2023-01-19